Announcements Trials
Browse Landscape

Phase

Phase 2 94Phase 1 57Phase 1/2 50Phase 3 9Phase EARLY_PHASE1 4Phase 2/3 2Phase NA 1Phase 4 1

Status

Recruiting 7Completed 6Active not recruiting 4Unknown 2Terminated 2Suspended 2Withdrawn 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 2

Interventions

Carboplatin 9Paclitaxel 8Gemcitabine 8Cisplatin 8Cyclophosphamide 7Fluorouracil 6Docetaxel 5Capecitabine 5Granulocyte Colony-Stimulating Factor 4Etoposide 4Vinorelbine 3Stem Cell Transplantation 3Radiotherapy 3Pemetrexed 3Melphalan 3Leucovorin 3Filgrastim 3Erlotinib Hydrochloride 3Bone Marrow Transplantation 3Bevacizumab 3umbralisib 2ublituximab 2pembrolizumab 2peginterferon alfa-2b 2fludarabine 2Whole-Body Irradiation 2Trastuzumab 2Transplantation, Homologous 2Surveys and Questionnaires 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Terminated × Nivolumab × Clear all
NCT04695977 2025-09-05

CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma

Regeneron Pharmaceuticals

Phase 2/3 Terminated
20 enrolled 18 charts
Dermatologic

Melanoma

NCT04901988 2025-02-27

DETECTION

The Christie NHS Foundation Trust

Phase 2/3 Terminated
8 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡